Literature DB >> 10353759

Suppression of telomerase, reexpression of KAI1, and abrogation of tumorigenicity by nerve growth factor in prostate cancer cell lines.

S Sigala1, I Faraoni, D Botticini, M Paez-Pereda, C Missale, E Bonmassar, P Spano.   

Abstract

Nerve growth factor (NGF) is expressed in the prostate, where it appears to be involved in the control of epithelial cell growth and differentiation. NGF production is decreased in prostate tumors. However, the role of this neurotrophin in the control of proliferation and progression of prostate cancers is still a matter of investigation. Prostate adenocarcinomas are telomerase-positive tumors. Chronic exposure of DU145 and PC3 prostate tumor cell lines to NGF resulted in a dramatic down-regulation of telomerase activity. This effect was correlated in terms of concentrations and time with a remarkable down-regulation of cell proliferation both in vitro and in vivo but was not secondary to NGF-induced quiescence. No down-regulation of telomerase activity was, in fact, detectable during serum starvation-induced quiescence. LNCaP cells, which do not express NGF receptors, appear to be insensitive to the actions of NGF. DU145 and PC3 cells do not express the KAI1 metastasis suppressor gene, which is present in the prostate and is progressively lost during the progression of prostate cancers. Chronic NGF treatment strongly induced the reexpression of this gene in these cell lines, and this effect was correlated with the suppression of their invasive potential in vitro. The data presented here suggest that NGF reverts two metastatic prostate cancer cell lines to slowly proliferating, noninvasive phenotypes characterized by a very low telomerase activity and by the expression of the KAI1 metastasis suppressor gene.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10353759

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  8 in total

1.  Telomerase enzyme inhibition (TEI) and cytolytic therapy in the management of androgen independent osseous metastatic prostate cancer.

Authors:  Yingming Li; Bahaa S Malaeb; Zhong-Ze Li; Melissa G Thompson; Zhi Chen; David R Corey; Jer-Tsong Hsieh; Jerry W Shay; Kenneth S Koeneman
Journal:  Prostate       Date:  2010-05-01       Impact factor: 4.104

2.  KAI1 metastasis suppressor gene is frequently down-regulated in cervical carcinoma.

Authors:  F S Liu; J T Chen; J T Dong; Y T Hsieh; A J Lin; E S Ho; M J Hung; C H Lu
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

Review 3.  Dissecting the diverse functions of the metastasis suppressor CD82/KAI1.

Authors:  Yien Che Tsai; Allan M Weissman
Journal:  FEBS Lett       Date:  2011-08-27       Impact factor: 4.124

4.  Phorbol ester enhances KAI1 transcription by recruiting Tip60/Pontin complexes.

Authors:  Alexandra Rowe; Jörg Weiske; Tobias S Kramer; Otmar Huber; Paul Jackson
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

5.  Genistein induces the metastasis suppressor kangai-1 which mediates its anti-invasive effects in TRAMP cancer cells.

Authors:  Lara H El Touny; Partha P Banerjee
Journal:  Biochem Biophys Res Commun       Date:  2007-07-16       Impact factor: 3.575

6.  Genes involved in differentiation, stem cell renewal, and tumorigenesis are modulated in telomerase-immortalized human urothelial cells.

Authors:  Emma J Chapman; Gavin Kelly; Margaret A Knowles
Journal:  Mol Cancer Res       Date:  2008-07       Impact factor: 5.852

7.  NGF inhibits human leukemia proliferation by downregulating cyclin A1 expression through promoting acinus/CtBP2 association.

Authors:  C B Chan; X Liu; S-W Jang; S I-H Hsu; I Williams; S Kang; J Chen; K Ye
Journal:  Oncogene       Date:  2009-08-10       Impact factor: 9.867

8.  Targeting the Nerve Growth Factor Signaling Impairs the Proliferative and Migratory Phenotype of Triple-Negative Breast Cancer Cells.

Authors:  Marzia Di Donato; Giovanni Galasso; Pia Giovannelli; Antonio A Sinisi; Antimo Migliaccio; Gabriella Castoria
Journal:  Front Cell Dev Biol       Date:  2021-06-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.